Her-2/neu Status and Tamoxifen Resistance in Breast Cancer
Author Information
Author(s): James Rani Thriveni K. Krishnamoorthy, Lakshmi Deshmane, Vijayalaxmi Bapsy P.P., Ramaswamy Girija
Primary Institution: Kidwai Memorial Institute of Oncology, Bangalore, India
Hypothesis
Does Her-2/neu expression in breast cancer patients predict tamoxifen effectiveness?
Conclusion
The study supports that Her-2/neu overexpression contributes to tamoxifen resistance in breast cancer patients.
Supporting Evidence
- 53 out of 207 patients were serum Her-2/neu positive.
- Patients treated with surgery, chemotherapy, and radiotherapy showed significantly reduced serum Her-2/neu levels.
- Patients treated with tamoxifen did not show significant reduction in serum Her-2/neu levels.
Takeaway
This study found that women with a certain protein called Her-2/neu in their breast cancer are less likely to respond to a common treatment called tamoxifen.
Methodology
The study used ELISA to measure serum Her-2/neu levels and immunohistochemistry to assess tissue Her-2/neu expression in breast cancer patients.
Participant Demographics
Majority of patients were aged 40 to 55 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website